Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim Blenman, Lajos Pusztai, Michał Marczyk et al.|Unknown|2023Cited by 0
Supplementary Data from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim Blenman, Lajos Pusztai, Julia Foldi et al.|Unknown|2023Cited by 0
Supplementary Data from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim Blenman, Lajos Pusztai, Michał Marczyk et al.|Unknown|2023Cited by 0
Supplementary Table from Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBCJulia Foldi, Lajos Pusztai, Adriana Kahn et al.|Unknown|2023Cited by 0
Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim Blenman, Lajos Pusztai, Michał Marczyk et al.|Unknown|2023Cited by 0